Designing a Seamless Transition Between Patient Support Vendors: A Strategic Framework for Biopharma

Executive Summary

Transitions between patient support program (PSP) vendors represent a critical inflection point for biopharma organizations. Recent developments are forcing manufacturers into these transition processes, as certain vendors have decided to exit the patient support business. While manufacturers might aim for a simple lift-and-shift, these instances are also natural opportunities to strategically evaluate the PSP’s current state, and where enhancements may be made with the next vendor.

When executed well, PSP vendor transitions preserve continuity of care, protect brand equity, and create opportunities to enhance the patient and provider experience. When mismanaged, they introduce friction, disrupt access, risk patient leakage, and destroy customer trust.

This blog outlines a high-level, pragmatic, phased approach to transitioning from an existing Patient Support Program (PSP) vendor, balancing operational rigor, patient-centric design, and forward-looking capability building.

1. Customer Needs Inventory

The first step is to establish a clear understanding of the post-prescription (post-Rx) treatment journey across the brands which will be affected by the PSP transition. This includes:

• Align On the Customer Journey: Internally align on maps of the patient and HCP journeys across access, onboarding, adherence, and persistence for each of the affected brands
• Validate Pain Points: Highlighting pain points, areas of friction, and leakage points, and validating these with field insights and operational data
• Anticipate Competitive Impact: Incorporate relevant anticipated competitive dynamics and how future launches may shift expectations in the marketplace

This step ultimately takes an evidence-based approach to clarifying what must be solved by the future vendor for each brand that is affected by the PSP vendor transition.

2. Current Service Gaps & Transition Dependency Analysis

The second step is to evaluate how well the current PSP vendor ecosystem meets the identified customer needs, and more importantly, what the new vendor must do differently.

• Assess Service Gaps: Compare existing services, tools, and capabilities against the prioritized customer needs to highlight unmet needs and opportunities for differentiation
• Identify Transition Dependencies: Surface critical operational dependencies, including:
  • Data architecture and migration requirements
  • Other vendors in the ecosystem and integrations needed with them
  • Internal processes and ownership structures
• Define Transition Success Metrics: Define clear KPIs for transition success (e.g., time-to-therapy, enrollment continuity, call center performance)

What comes out of this step is a clear articulation of what must be preserved, improved, or rebuilt, and the constraints shaping the transition from the current PSS vendor to the future one.

3. Future Vendor Requirement Articulation & Evaluation

This step translates insights from the first two steps into a vendor-facing document to communicate what is being asked of them, and how their capabilities will be assessed. Following that, the potential vendors must be evaluated and strategic fit determined.

Doing this will involve:

• Vendor Requirement Definition: Define required services, capabilities, and technology infrastructure needed from potential future vendors, and establish expectations for:
  • Data migration and interoperability
  • Compliance and regulatory alignment
  • Business continuity and patient experience protection
• Requirement Communication: The above vendor requirements must be formally issued to potential new PSP vendors (e.g. as an RFP or other structured briefing)
• Vendor Scorecard Creation: Align internally on how potential vendors will be assessed, incorporating:
  • Capability depth and scalability
  • Transition readiness, timeline feasibility, and risk mitigation approaches
  • Experience in similar therapeutic or operational contexts
• Model Alignment (optional): If multiple brands across different therapeutic areas and indications are affected by the transition, evaluate single- vs. multi-vendor modalities based on
  • Complexity of customer needs
  • Integration requirements
  • Risk diversification considerations

By the end of this step, there should be a clear selection of a new PSP vendor that is best fit to take over the void left by the departing vendor, based on a structured set of requirements aligned to both current gaps and future ambition.

4. Transition Plan Development

This final step will look to operationalize the transition through a detailed, executable roadmap.

Core elements include:

• Transition timeline and milestones, aligned to business priorities
• Communication strategy, including:
  • Internal stakeholders (field, access, patient services)
  • External audiences (patients, providers, advocacy groups)
• Parallel run and validation strategy (where feasible) to de-risk cutover
• Transition governance structure and escalation pathways

This step wraps things up with a comprehensive transition plan designed to ensure continuity, minimize disruption, and enable rapid stabilization.

Note on an Acceleration Opportunity to these Steps:

Depending on how quickly the PSP vendor transition must occur, steps 1 and 2 can be streamlined where strong documentation and internal alignment already exist. However, even in accelerated scenarios, validating real-world patient and provider experience remains critical to avoiding blind spots.

Conclusion

A vendor transition is more than a procurement exercise. It is an opportunity to redefine the patient support model in line with evolving expectations and competitive pressures.

By anchoring decisions in customer needs, rigorously assessing current gaps, and executing the transition with operational discipline, organizations can turn a high-risk transition into a strategic advantage.